Molecular analysis of compensatory mechanism which tumor cells exert in VEGF deficent/RipTag mouse

VEGF缺陷/RipTag小鼠肿瘤细胞代偿机制的分子分析

• 批准号: 15590363
• 负责人: INOUE Masahiro
• 金额: $ 1.98万
• 依托单位: Osaka Medical Center for Cancer and Cardiovascular Diseases
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2004
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-15590363/
• 关键词: angiogenesis; VEGF; transgenic mouse; gene knockout mouse; hypoxia; 遺伝子発現

While we transferred RipTag mice from university of California at San Francisco, we found profound reduction of tumor formation in Japan. Formation of tumor in RipTag mouse is known to be sensitive to the genetic background. Although we tried to resolve the problem by backcrossing it into C57B1/6N or DBA background, we did not observe remarkable recovery of tumor formation. Afterwards, it has been revealed that the same phenomenon was observed in the original mouse colony in UCSF. It is likely that some genomic change in RipTag mouse occurred. Re-establishment of the transgenic mouse is now under consideration. Meanwhile, analysis of the archive pancreas samples from RipTag/VEGF-/- mice revealed that there were residual tumors with quite low microvessel density without apparent necrosis. We found that the residual tumors contains broad hypoxic region. This finding suggests that inhibiting angiogenesis results in emergence of hypoxic region as well as reduction of tumor formation. In these hypoxic tumors, apoptosis was not significantly increased, tumor cells seems to survive by adapting to the hypoxic microenvironment. From clinical point of view, the results offered a serious issue that anti-angiogenesis therapy might induce drug resistance by selecting hypoxia tolerant cancer cells. Then, We started to investigate the molecular mechanism of hypoxia tolerance of malignant cells. We found various cell lines can be maintained in hypoxic conditions for a couple of weeks. These tumor cells were alive but no proliferation nor cell death was observed. We focused on the mTOR signaling, which is know to be suppressed in hypoxia, but the consequence has not been clarified yet. We revealed that suppression of mTOR signaling is critical for their survival under prolonged hypoxic conditions.

当我们从旧金山加利福尼亚大学转移 RipTag 小鼠时，我们发现日本的肿瘤形成显着减少。已知 RipTag 小鼠肿瘤的形成对遗传背景敏感。尽管我们尝试通过将其回交至C57B1/6N或DBA背景来解决该问题，但我们没有观察到肿瘤形成的显着恢复。后来发现，在UCSF的原始小鼠群体中也观察到了同样的现象。 RipTag 小鼠的基因组很可能发生了一些变化。目前正在考虑重建转基因小鼠。同时，对RipTag/VEGF-/-小鼠存档胰腺样本的分析显示，存在残留肿瘤，微血管密度相当低，无明显坏死。我们发现残留肿瘤包含广泛的缺氧区域。这一发现表明，抑制血管生成会导致缺氧区域的出现以及肿瘤形成的减少。在这些缺氧肿瘤中，细胞凋亡并没有显着增加，肿瘤细胞似乎通过适应缺氧微环境来生存。从临床角度来看，该结果提出了一个严重的问题，即抗血管生成治疗可能通过选择耐缺氧的癌细胞来诱导耐药性。随后，我们开始研究恶性细胞耐缺氧的分子机制。我们发现各种细胞系可以在缺氧条件下维持几周。这些肿瘤细胞是活的，但没有观察到增殖或细胞死亡。我们重点关注 mTOR 信号传导，已知该信号传导在缺氧时会受到抑制，但其后果尚未明确。我们发现，抑制 mTOR 信号传导对于它们在长期缺氧条件下的生存至关重要。

项目成果

Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites.

用蛋白质前药靶向缺氧癌细胞对于实验性恶性腹水是有效的。

• 发表时间: 2004
• 期刊: Int J Oncol 25
• 作者: Inoue;M.;et al.
• 通讯作者: et al.

Cyclic phosphatidic acid inhibits RhoA-mediated autophosphorylation of FAK at Tyr-397 and subsequent tumor-cell invasion

环磷脂酸抑制 RhoA 介导的 Tyr-397 处 FAK 自身磷酸化和随后的肿瘤细胞侵袭

• 发表时间: 2003
• 期刊: Int. J. Oncology 22
• 作者: R.Ishihara;M.Tatsuta;H.Iishi;M.Baba;N.Ucdo;K.Higashino;M.Mukai;S.Ishiguro;S.Kobayashi;K.Murakami-Murofushi;向井睦子
• 通讯作者: 向井睦子

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis

• DOI: 10.1172/jci200422087
• 发表时间: 2004-09-01
• 期刊: JOURNAL OF CLINICAL INVESTIGATION
• 影响因子: 15.9
• 作者: Giraudo, E;Inoue, M;Hanahan, D
• 通讯作者: Hanahan, D

Hoffman, J., Giraudo, E., Singh, M., Inoue, M et al.: "Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma."Cancer Cell. 4. 383-391 (2003)

Hoffman, J.、Giraudo, E.、Singh, M.、Inoue, M 等人：“鳞状细胞癌转基因小鼠模型中的进行性血管变化。”癌症细胞。

Kizaka-Kondoh, S., Inoue, M., Harada, H., Hiraoka, M: "Tumor Hypoxia : a Target for Selective Cancer Therapy"Cancer Science. 94. 1021-1028 (2003)

Kizaka-Kondoh, S.、Inoue, M.、Harada, H.、Hiraoka, M：“肿瘤缺氧：选择性癌症治疗的目标”癌症科学。